Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • InnoRNA

    - PMLiVE

    BeiGene’s Tevimbra combination granted EC approval in small cell lung cancer

    Approximately 15% of all lung cancer patients are diagnosed with the aggressive disease

    - PMLiVE

    BeiGene’s Tevimbra recommended by CHMP to treat small cell lung cancer

    The aggressive form of lung cancer accounts for around 15% of all cases of the disease

    - PMLiVE

    BeiGene’s Tevimbra approved by FDA for first-line oesophageal cancer use

    Oesophageal squamous cell carcinoma accounts for nearly 90% of all oesophageal cancers

    - PMLiVE

    BeiGene’s Tevimbra combination granted FDA approval to treat gastric cancer

    Approximately 27,000 cases of the disease were diagnosed in the US in 2024

    - PMLiVE

    BeiGene’s Tevimbra approved by EC for first-line gastric and oesophageal cancer use

    Gastric cancer is the fifth leading cause of cancer-related deaths globally and oesophageal cancer is the sixth

    - PMLiVE

    BeiGene’s Tevimbra recommended by CHMP for gastric and oesophageal cancer

    Gastric cancer is the fifth leading cause of cancer-related deaths globally, while oesophageal cancer is the sixth

    - PMLiVE

    BeiGene’s Brukinsa recommended by NICE to treat marginal zone lymphoma

    Approximately 2,600 cases of the blood cancer are diagnosed in the UK every year

    - PMLiVE

    BeiGene’s Tizveni receives EC approval to treat non-small cell lung cancer

    Under the brand name Tevimbra, the company will combine the NSCLC indications with the second-line ESCC indication in late 2024

    - PMLiVE

    BeiGene’s Tevimbra receives FDA approval to treat advanced oesophageal cancer

    More than two-thirds of patients have advanced or metastatic disease at the time of diagnosis

    - PMLiVE

    BeiGene’s Brukinsa granted FDA accelerated approval for advanced follicular lymphoma

    Approximately 15,000 new cases of follicular lymphoma are diagnosed in the US every year

    - PMLiVE

    BeiGene’s tislelizumab receives CHMP recommendation for non-small cell lung cancer

    Lung cancer is the second most common type of cancer and the leading cause of cancer-related death globally

    - PMLiVE

    Almirall and etherna partner to develop mRNA-based therapies for severe skin diseases

    Dermatological diseases are estimated to affect 1.8 billion people worldwide

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links